Peripheral blood IFN-γ-producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor-based therapy.

ABSTRACT:

Background

Immune checkpoint inhibitor(ICI)-based therapy has revolutionized non-small-cell lung cancer (NSCLC) treatment, yet reliable biomarkers for monitoring immune response in real time remain elusive.

Materials and methods

In NSCLC patients, lymphocyte counts and function through interferon (IFN)-γ secretion in CD4⁺, CD8⁺ T cells and NK cells were detected prior to therapy, at day 21 post therapy by flow cytometry. We also dynamically assessed alterations in the cytokines tumor necrosis factor-alpha, interleukin (IL)-2R, IL-6 and IL-8, establishing the clinical utility in predicting ICI-based therapy outcomes.

Results

The study found that different therapies induced distinct patterns of immune remodeling. ICI-based therapy significantly inc

SUBMITTER: Wang C 

PROVIDER: S-EPMC13473051 | biostudies-literature | 2026 Jun

REPOSITORIES: biostudies-literature